Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Thyroid. 2013 Feb;23(2):185-93. doi: 10.1089/thy.2012.0327.
The thyrotropin (TSH) level or duration of thyroid hormone withdrawal (THW) required to detect stimulated thyroglobulin (Tg) in differentiated thyroid cancer (DTC) monitoring is unknown. The objective of this study was to evaluate the TSH cutoff of >30 μU/mL as a means to detect stimulated Tg ≥2 ng/mL after THW (THW-Tg≥2), and sensitivity of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire for detecting hypothyroid symptoms.
This was a prospective longitudinal cohort study done at a tertiary academic medical center. Forty-seven patients with DTC undergoing their first Tg stimulation or after previously abnormal Tg stimulation had weekly measurements of TSH and Tg during the 4 weeks THW, and repeated questionnaire assessments.
TSH did not reach a plateau in any patient, and in those whose Tg did not remain undetectable, Tg continued to rise. Seventy-five percent of patients had an undetectable Tg <0.2 ng/mL at baseline (95% were <0.5 mg/mL) with 16% remaining undetectable throughout THW. The majority of patients (72.7% and 97.8%) achieved TSH >30 μU/mL by 3 and 4 weeks THW, respectively. Of the 15 patients with maximum stimulated THW-Tg≥2, 38% were detected before the minimal TSH >30 μU/mL cutoff. At 2 weeks THW, 3 had a TSH>30 μU/mL, and none of them had Tg ≥2 ng/mL. At 3 weeks THW, 11 had a TSH >30 μU/mL, and 64% of them had Tg ≥2 ng/mL. Only 60% were detected at 3-week THW regardless of their TSH level. Eighty-six percent were detected by TSH 60-<80 μU/mL. Conversely, all patients whose serum Tg was <0.2 ng/mL when their serum TSH was >20 μU/mL did not achieve a THW-Tg≥2.
The minimal TSH cutoff of >30 μU/mL was inadequate to detect many patients with final stimulated THW-Tg≥2 during complete THW. TSH >80-100 μU/mL was a better cutoff, achieved in only 53% after 4-week THW. Conversely, we propose a preliminary THW-stopping rule for ending THW early in selected patients. In patients with a Tg <0.2 ng/mL when TSH >20 μU/mL, all had a final stimulated Tg ≤2 ng/mL, potentially saving qualifying patients 40% of THW duration compared to 4-week THW. FACIT-F correlated with TSH, but was not sensitive to detect mild hypothyroidism.
在分化型甲状腺癌(DTC)监测中,检测刺激后的甲状腺球蛋白(Tg)所需的促甲状腺激素(TSH)水平或甲状腺激素停药(THW)时间尚不清楚。本研究旨在评估 TSH>30μU/ml 作为检测 THW 后 Tg 刺激≥2ng/ml(THW-Tg≥2)的方法,并评估慢性疾病治疗疲劳量表功能评估(FACIT-F)问卷检测甲状腺功能减退症状的敏感性。
这是一项在三级学术医学中心进行的前瞻性纵向队列研究。47 例首次进行 Tg 刺激或之前 Tg 刺激异常的 DTC 患者,在 THW 的 4 周内每周测量 TSH 和 Tg,并重复进行问卷评估。
在任何患者中,TSH 均未达到平台期,而在 Tg 仍未检测到的患者中,Tg 继续升高。75%的患者在基线时 Tg<0.2ng/ml(95%<0.5mg/ml),其中 16%的患者在整个 THW 期间仍无法检测到 Tg。大多数患者(72.7%和 97.8%)分别在 3 周和 4 周 THW 时达到 TSH>30μU/ml。在 15 例最大刺激 THW-Tg≥2 的患者中,38%在最小 TSH>30μU/ml 截止值之前被检测到。在 2 周 THW 时,有 3 例 TSH>30μU/ml,但均无 Tg≥2ng/ml。在 3 周 THW 时,有 11 例 TSH>30μU/ml,其中 64%的 Tg≥2ng/ml。无论 TSH 水平如何,仅在 3 周 THW 时检测到 60%的患者。86%的患者在 TSH 60-<80μU/ml 时被检测到。相反,所有在 TSH>20μU/ml 时血清 Tg<0.2ng/ml 的患者最终均未达到 THW-Tg≥2。
最小 TSH 截止值>30μU/ml 不足以在完全 THW 期间检测到许多最终刺激 THW-Tg≥2 的患者。TSH>80-100μU/ml 是一个更好的截止值,仅在 4 周 THW 后达到 53%。相反,我们提出了一种用于在选定患者中早期终止 THW 的初步 THW 停止规则。在 TSH>20μU/ml 时 Tg<0.2ng/ml 的患者中,所有患者的最终刺激 Tg≤2ng/ml,与 4 周 THW 相比,可能使合格患者的 THW 持续时间缩短 40%。FACIT-F 与 TSH 相关,但对检测轻度甲状腺功能减退不敏感。